NLS Pharmaceutics to Present New Data on the Dual Efficacy of Mazindol ER in Fentanyl Reward and Withdrawal at the 2025 ASCP Annual Meeting

ZURICH, May 21, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP), a Swiss clinical-stage biopharmaceutical company focused on central nervous system ("CNS") disorders, announces that it will present new preclinical data on Mazindol ER at the 2025 Annual Meeting of the American...

Read More